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Introduction
Tumors exhibit abnormal epigenetic regulation (1). A key epigenetic event is DNA methylation, typically at the dinucleotide CpG. Both hypomethylation and hypermethylation of DNA is observed in cancer cells. Generally, the former leads to activation of protooncogenes and the latter to repression of tumor suppressors during the initiation and progression of cancer. The Methyl-CpG-Binding Domain (MBD) family of proteins is among the ones that bind methylated DNA directly and this association is critical in regulating the outcome of DNA methylation (2,3). The MBD family includes proteins named MBD1, MBD2, MBD4 and MeCP2. (MBD3 contains the MBD but does not bind methylated DNA directly.) The molecular events leading from DNA methylation or demethylation to gene regulation during cancer progression are poorly defined. In this study, the binding of MBD proteins throughout the entire genome of several malignant prostate tumors and matched normal or benign tissues will be identified. This provides novel fundamental information about epigenetic regulation during carcinogenesis. Also, the differences in these patterns will identify new genes regulated by MBD binding and DNA methylation during prostate cancer progression. These genes potentially identify novel biomarkers or therapeutic targets.
The identity of bound MBD protein will facilitate subsequent studies that examine the "downstream" molecular events at a specific gene during progression of prostate cancer.
Body
As a brief overall summary, the genomic profiles of MBD proteins in malignant and matched normal or benign prostate tissue was examined by Chromatin Immunoprecipitation (ChIP) followed by Next Generation Sequencing (NGS or Seq).
The details of the ChIP-Seq experiments are described below. The subsequent bioinformatics analysis of this project was performed to identify genes potentially targeted and regulated by MBD proteins -described below. This downstream informatics analysis was demanding because MBD proteins are associated with the genome over wide regions, a major difference from "typical" DNA-binding proteins such as CREB or C/EBP which bind relatively small and discrete recognition sites and the bioinfomatic analysis required increased effort. The pattern of MBD binding is similar to that observed with many histone modifications, another form of epigenetic regulation. One thing I have learned from this study is that additional information can be obtained and questions addressed with continued bioinformatic approaches, almost ad infinitum, so this analysis will be a continuing process. In the following summary, I have attempted to include representative and important analyses.
The first task includes the Chromatin Immunoprecipitations (ChIP) and Next Generation Sequencing (NGS or Seq) experiments. Five sets of matched malignant prostate carcinomas and normal/benign prostate tissues were obtained from the Cooperative Human Tissue Network (http://www.chtn.nci.nih.gov). These tissues were divided into two portions. The larger portion was prepared for ChIP experiments using the truChIP Tissue Chromatin Shearing Kit (Covaris, Woburn, MA). (The smaller portion of tissue was used for isolation of RNA -see below.) Briefly, the tissues were minced, treated with formaldehyde and this reaction was quenched per manufacturer's suggested protocol. Each tissue was disrupted and the separated cells that resulted were lysed. The nuclei were collected by centrifugation, then sonicated to lyse the nuclei and shear the chromatin in an Adaptive Focused Acoustics sonicator (Covaris). Chromatin immunoprecipitations were carried out using antibodies that recognize MeCP2, MBD1, MBD2 and MBD4 and the ChIP-IT High Sensitivity Kit (Active Motif, Carlsbad, CA). The resulting "ChIP DNA" was quantified using a Qubit fluorometer (Life Technologies, Grand Island, NY), then concentrated and purified by ethanol precipitation using linear acrylamide as a carrier and quantified again at the end using the Qubit fluorometer. The amounts of DNA obtained after the ChIP and ethanol precipitation made the next step, the preparation of libraries for Next-Generation Sequencing, technically challenging and required more time than allotted in the "Statement of Work". This delay led to the request and approval of a no-cost extension on the grant.
The SeqPlex DNA Amplification Kit (Sigma, St Louis, MO) was used to generate the libraries for NGS following the manufacturer's suggested protocol. ChIP DNA from three matched sets of malignant prostate cancer and normal/benign prostate tissue were sequenced using the Ion Torrent (Life Technologies).
Approximately 1 million sequencing "reads" were performed for each sample. With additional resources, a higher number of reads per sample might increase the number of identifiable peaks (that reach the appropriate statistical threshold).
The second task will be brought into the discussion at this point, prior to the bioinformatics analysis portion of Task 1, because the information from the microarrays performed in the second task was used in the bioinfomatic analysis. In brief, RNA was isolated from the prostate tissues, a microarray was performed to identify genes that are differentially expressed in malignant prostate tissues and in the bioinformatic analysis, this information was correlated with binding of MBD
proteins. An mRNA fraction was isolated from each tissue using an RNeasy Kit and a Qiacube (Qiagen USA, Valencia, CA). (In addition, microRNA fractions have been isolated from two sets of matched tissues to expand this study to include microRNAs in the future.) Equal amounts of mRNA from three normal prostate tissues and from three stage 3 malignant prostate carcinomas, respectively, were mixed and assayed using an Affymetrix microarray. Using this pooled set of mRNAs, the microarray experiment was used to generate a list of genes that are increased >2-fold and decreased >2-fold in the stage 3 prostate cancer tissue relative to normal tissue (see Tables 1 and 2 in Supporting Data for 98 most up-regulated and down-regulated genes). Genes of interest, namely their expression levels, will need to be validated by reverse transcriptase-quantitative PCR (RT-qPCR) using mRNAs from matched sets of tissues. The threshold of 2-fold is arbitrary and gene lists using different thresholds can be generated easily.
The bioinformatics analysis (part of Task 1) was used to address different questions. As a brief introduction of the bioinfomatic analysis, "alignment" refers to the process of identifying (or aligning) the sequence reads against the reference genome, in this case the hg19 compilation of the human genome. This process records the sequencing reads attributable to each genomic region. After the alignments are performed, they are compared between MBD-family ChIPs and either input DNA or an IgG-control ChIP to identify "peaks" or "regions" of aligned sequence reads within the genome. The chromosomal locations and corresponding genes within those peak regions are analyzed to identify potential MBD targets.
In one analysis, the alignments produced by the software of the Ion Torrent sequencer were used. These results were then processed (in collaboration with H.
Chen) in a software package called RSEG (4) to identify the boundaries of the peaks from the ChIP-Seq experiments. RSEG was developed to identify the boundaries of broad, less discrete peaks such as those associated with histone modification. This property makes it useful for the analysis of MBD binding profies. The peaks identified by RSEG were analyzed using the tools within the Galaxy website (https://usegalaxy.org) to identify genes that overlap the peaks. An alternative analysis is using the commercially available Genomics Suite -ChIP-Seq workflow (Partek, St Louis MO), which has been used in other publications (4, 5). The analysis using RSEG/Galaxy and Genomics Suite (Partek) will be described below.
The bioinformatics is an on-going task. The analysis above is being continued to extract additional information and results for publication. The bioinformatics analysis (in collaboration with Q Tran) is also being performed in a third way for comparison using Bowtie (www.bowtie-bio.sourceforge.net) to perform the alignments and MACS (http://liulab.dfci.harvard.edu/MACS/) to identify the peaks. This is ongoing and not described below.
The analysis of the MBD1 ChIP-Seq experiments using RSEG and Galaxy to identify and analyze **malignant-specific** MBD1 ChIP-Seq peaks is summarized next. MBD1 ChIP-SEQ was performed using three matched sets of malignant and normal/benign prostate tissues. As described above, RSEG was used to identify the MBD1 ChIP-Seq peaks from matched malignant and normal or benign tissues. Using Galaxy, the MBD1 ChIP-Seq peaks specific to the malignant tissue of each sample were identified by subtracting the peaks from the normal or benign tissue from the peaks present in the matched malignant prostate tissue. These resulting peaks from each of three sets of samples were compared and 32 malignant-specific MBD1 peaks common to all three samples were identified (see Table 3 ). There is a large difference in the number of common peaks identified when all three samples are compared versus the pair-wise comparisons. When the malignant-specific MBD1 peaks were compared in a pair-wise manner, 164, 94 and 483 common peaks (or genomic regions) were identified (list of peaks not shown). The malignant-specific MBD1 peaks common to all three samples were analyzed to identify regions containing known genes. Of these 32 peaks, most are gene-containing region and this analysis yielded 31 malignant-specific peaks (see Table 4 ). These 31 genecontaining regions were examined using Integrated Genome Browser (IGB; www.bioviz.org). Twenty-six of these regions contain 6 genes or less (data not shown). The relative expression level of the genes from these 26 regions in malignant versus normal prostate tissues was compared using the complete microarray results described above. Of these 26 regions, nineteen contain just one or two genes. (Note: One, some genes within these 26 regions were not found within the microarray and levels could not be determined from that experiment. Two, the regions beyond the 26 above were not investigated further because they contain between 10 and 33 genes. The large number of genes in these regions greatly diminishes the value of the analysis.) Of the genes overlapping the malignant-specific MBD1 peaks common to all three tissue samples, five genes had decreased levels of RNA in malignant tissues: SLC22A15, FAM110C, PLEKHG4B, PDCD6 and HRSP12 (listed in Table 4 ). Decreased expression was defined as RNA level less than 80% of that observed in normal tissues. Of these investigated genes, six genes had at least 1.4-fold increased RNA level in malignant relative to normal tissues: CASQ2, DPF3, KIAA0226, CCDC127, PTPRN2 and snoRNA72 (listed Table 4 A similar analysis using RSEG and Galaxy was used to examine the MeCP2
ChIP-Seq experiments and identify and analyze malignant-specific MeCP2 ChIP-Seq peaks. MeCP2 ChIP-Seq was performed using the same three matched sets of malignant and normal/benign prostate tissues as used in the MBD1 study above.
RSEG was used to identify the boundaries of the ChIP-Seq peaks. Using Galaxy, the malignant-specific MeCP2 ChIP-Seq peaks for each sample were identified as described above. These resulting peaks from each of three sets of samples were compared and 38 malignant-specific MeCP2 peaks common to all three samples were identified (see Table 5 ). For comparison, when the malignant-specific MeCP2 peaks were compared in a pair-wise manner between samples, there were 1835, 462 and 1815 common peaks were identified (peak lists not shown). The malignantspecific MeCP2 peaks common to all three matched samples were analyzed to identify regions that contained known genes within these common peaks. Of these 38 peaks, most contained genes and this analysis yielded 29 malignant-specific peaks (see Table 6 ). These 29 genomic regions were examined using Integrated Genome Browser. Twenty-three of these regions contain 7 genes or less (data not shown). The relative expression level of these genes in malignant versus normal prostate tissues was compared using the complete microarray results described above. (NOTE: Of these 23 regions, fifteen contain just one or two genes. The remaining regions, which contain between 11 and 20 genes, will not be analyzed further at this time because the large number of genes.) Of the genes overlapping the malignant-specific MeCP2 peaks common to all three tissue samples, five genes had decreased levels of RNA in malignant tissues: SORC3, C11orf45, ACOXL, GINS1 and GRIA1 (listed in Table 6 ). Decreased expression was defined as RNA level less than 80% that observed in normal tissues. Of these investigated genes, six genes had at least 1.4-fold increased RNA level in malignant relative to normal tissues: RPS6KC1, CDH11, PTPRM, LYPD1, NCKAP5 and PTPRT (listed in Table 6 ). Some of the noteworthy features of these genes include the role of: SORC3 in vacuole sorting, the association of ACOXL with leukemias, GIN, an replication initiation factor which contains GINS1 as a subunit, RPS6KC1 in regulating protein synthesis, CDH11's involvement in signaling as a cadherin, PTPRM and PTPRT which are both receptors containing tyrosine phosphatase activity and LYPD1 (also known as C4. 4) in tumor metastasis. Additional experiments to examine gene expression levels and additional literature research investigating protein function are needed.
The MBD4 ChIP-Seq experiments were analyzed in order to identify the malignant-specific peaks. In this case, the ChIP-Seq data from just two of three matched tissue sets used in the MBD1 and MeCP2 studies above was obtained.
RSEG and Galaxy were used as described above to identify the malignant-specific MBD4 ChIP-Seq peaks for each sample. This analysis for MBD4 will be described in a bit more detail than for MBD1 and MeCP2 to provide some insight into the number of peaks that were typically identified in the ChIP-Seq experiments. In one set of matched tissues, 1173 malignant-specific peaks were identified out of 1,936 peaks identified from the malignant tissue. In the second set of matched tissues, 760 malignant-specific peaks were identified out of 1,130 peaks. When the malignantspecific peaks are compared, 143 overlapping malignant-specific peaks between these two tissues were identified (see Table 7 ). The genes within these peaks will be identified and expression will be examined using the previously discussed microarray and additional experiments such as RT-qPCR or microarrays.
MBD2 ChIP-Seq data was also obtained for only two of three matched sets of tissues used in the MBD1 and MeCP2 studies above. The analysis was performed as described for MBD4. The overlapping malignant-specific peaks will be analyzed for overlapping genes and gene expression will be examined further.
The analysis performed using Genomics Suite is described next. The first part of the analysis is aimed at identifying the sites where the methyl CpG-binding domains proteins are associated. Briefly, the raw high-throughput sequencing data was aligned against a reference human genome (hg19) to identify peaks (also called "regions"). The alignment was performed in pairs -experimental ChIP DNA and input DNA from malignant or normal/benign samples. The peaks that passed the criterion of a false discovery rate (FDR) equaling 0.2 or less were identified, then the peaks found in the experimental ChIP sample or not and those found in the input DNA or not were sorted. The peaks that were found in the experimental ChIP were filtered to find the ones that are specific to the ChIP (that is, not found in the input). The outcome of these operations is to identify peaks (i.e., regions within the genome) associated with the corresponding methyl CpG-binding domain protein (MBD1, MBD2, MBD4 or MeCP2).
MBD1 ChIP-Seq results were obtained from three matched sets of samples -(Sample or Patient) #3, #4 and #6. Using the Partek Genomics Suite software, the normal tissue samples 1897, 1491 and 1257 peaks (also called "regions"), respectively, were identified in the normal tissues and 1826, 1814 and 1355 peaks, respectively, were identified in the malignant tissues. Of the 1897 identified peaks (or "regions") found in the normal tissue of sample #3, 1234 peaks were identified in the MBD1 ChIP and 1329 peaks were identified in the input DNA. This distribution was roughly similar for all samples (malignant, normal or benign and each ChIP -MBD1, MBD2, MBD4 and MeCP2). In our continued analysis, we found that 217 of the 1897 peaks from Sample #3 normal tissue passed the false discovery rate (FDR). Of those 42 were specific to the MBD1 ChIP (that is, the peaks were NOT present in the Input DNA). These MBD1-specific peaks are listed in Table 8 and are predicted to correspond to genomic regions where MBD1 is associated in the normal tissue from Sample #3. Continuing with the Partek Genomics Suite, when it was used to identify genes within 10 kb of the peaks, those 42 peaks yielded a set of 41 Transcript IDs (see Table 9 ). It should be noted that many of the Transcript IDs correspond to the same gene (symbol). Based on these results, the peaks (Table 8 ) and gene list (Table 9) Tables 8-15 including a list of normal tissue-specific peaks and malignant specific peaks for Sample (or Patient) #3 and closest genes to normal-specific peaks and malignantspecific peaks for all three Samples (Patient #3, #4 and #6). This set of tables is listed in the Supporting Data at the end, but it is also listed below to help clarify what is present. were not included in an attempt to minimize the number of tables in this document.
I need to address an important technical point regarding the analysis performed on Partek Genomics Suite. One, as this analysis was being performed, the small number of common sites was surprising. I followed up this point in two ways. I used the "genome browser" function which allows me to visually compare peaks in different samples and found that some common sites seemed to be present that were not being identified by the software package. A visual inspection is one method for identifying the common peaks. While the visual inspection of one chromosome for comparison is possible, each autosomal and sex chromosome is presented separately so ChIP-Seq of each tissue would require 24 visual inspections (22 autosomal, X and Y chromosomes). This is impractical. That is part of the reason that RSEG/Galaxy and Bowtie/MACS was/is being used for this analysis. Two, I
attempted to identify common peaks in three related sets of results simultaneously.
This software package is supposed to have the capability to perform this analysis, but the output in three columns was not making sense. After discussions with customer support at Partek, it is likely there is a "bug".
The first task was broken down into four parts and the first three parts (perform ChIPs, prepare samples for NGS and perform NGS) have been completed. Two matched malignant/normal tissue samples and one matched malignant/benign sample was used in our ChIP-Seq studies. The bioinformatic analysis is the fourth task and some important and representative analysis has been presented in this report. The bioinformatics analysis will be continued to generate additional information. The second task is identifying both genes that are differentially expressed in malignant prostate tissues and corresponding gene promoters that differentially bound by MBD proteins in malignant prostate tissues. Microarray experiment has been performed and those results have been used to generate correlations between sites of MBD family association and differentially regulated genes in malignant tissues. The steps involved in the two tasks have been detailed above.
The third task is the writing and submission of a manuscript. The delay involved in preparing samples for NGS and the time-consuming nature of the data analysis has meant that this task has not been completed. The results described above will be used in the future for both a manuscript and in grant applications.
Key Research Accomplishments
-Chromatin Immunoprecipitation using matched malignant and normal/benign prostate tissues were performed with antibodies directed against MeCP2, MBD1, MBD2 and MBD4 (methyl-CpG binding domain containing proteins)
-"Next Generation Sequencing of ChIP experiments described was performed.
-The bioinformatics analysis of NGS data has been undertaken. Bioinformatic analysis is still on-going. Differences in the MBD association profiles between matched tissues were observed. Genes overlapping the binding sites of MBD proteins were identified. The microarray analysis was used to determine which of the overlapping genes were up-regulated or down-regulated.
-mRNAs has been isolated from each tissue. Small RNAs (miRNAs being of interest) have been isolated from some matched tissues. 
Conclusions
This study has identified the association sites of MBD family members in matched malignant and normal or benign prostate tissues through ChIP-Seq experiments and bioinformatics analysis, then used these results to identify genes that overlap these regions. These results are important because they provide a genome-wide entry to understanding one type of epigenetic regulation that is often involved in cancer. The implication is that some of the sites or regions of MBD1, MBD2, MBD4 and MeCP2 association that are specific to malignant tissues are important to tumor progression. From a technical stand-point, this study is useful in contributing to early, but growing, literature that ChIP-Seq can be used on clinical (patient) samples.
The results are summarized by a variety of tables -in the supporting datathat list the malignant-specific association sites for these MBD-family members and the regions containing overlapping genes and the microarray analysis. This information generates two types of scientific hypotheses. One, that the identified genes are involved in tumor progression and that the association of MBD family members regulates their expression in a manner that leads to cancer. Two, that the identified genes may not be involved in tumor progression but their expression changes may be useful as biomarkers. In the future, I will propose studies to characterize those hypotheses for selected genes. By increasing the understanding of gene regulation leading to malignant cancers, a critical mass will be reached where the disease can be addressed in a differential manner. Cancer is such a complicated disease that ideas of "one size fits all" are naïve. However, a more robust understanding of the basic science underlying the process will allow clinicians to determine the specific pathways have been corrupted, how the pathways intertwine and the stage of the process and thus tailor treatment accordingly. 
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